Calcineurin Inhibitors for Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (ACR Convergence 2023) - Sep 24, 2023 - Abstract #1509; Pres time: Nov 13, 2023; 09:00 AM - 11:00 AM; Location: Poster Hall; in person; "Studies were eligible if they included (P) patients with biopsy-proven LN, (I) compared CNI (voclosporin, tacrolimus, and CSA) alone or in combination with other immunosuppressors against (C) the SoC (MMF or CYC), (O) for efficacy (complete and partial renal response [CR and PR, respectively]) and safety (death, infections, gastrointestinal adverse effects [GIAE], cytopenias)... Patients with LN treated with CNI for the induction of remission may have better response compared with MMF or CYC. CNI might be considered as equally safe in mortality and infections as the SoC. Possibly CNI might have less GIAE and cytopenias than the SoC, particularly compared with CYC."
Retrospective data • Review • Gastrointestinal Disorder • Glomerulonephritis • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Gabriel Figueroa-Parra1; Maria Cuellar-Gutierrez1; Mariana Gonzalez-Trevino1; Larry J. Prokop2; M. Hassan Murad3; Ali Duarte-Garcia4
|